BioPharmSignal logoBioPharmSignal

Biotech News

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics (CADL)Candel TherapeuticsCompany update

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31,

Related news

CADLCandel Therapeutics2026-09-10 12:05 EST

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

CADLCandel Therapeutics2026-08-26 12:05 EST

Candel Therapeutics to Present at September Investor Conferences

FATEFate Therapeutics2026-08-03 20:05 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-09-18 20:01 EST

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-09-04 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZNTLZentalis2026-09-01 21:15 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IDYAIDEAYA Biosciences2026-08-28 10:00 EST

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ERASErasca2026-08-10 20:01 EST

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GERNGeron2026-07-14 20:26 EST

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

Candel Therapeutics

Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into...

Recent company news

CADLCandel Therapeutics2026-09-10 12:05 EST

Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors

CADLCandel Therapeutics2026-09-01 20:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CADLCandel Therapeutics2026-08-26 12:05 EST

Candel Therapeutics to Present at September Investor Conferences

CADLCandel Therapeutics2026-08-13 12:05 EST

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

CADLCandel Therapeutics2026-08-03 20:05 EST

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
11.34 USD
Market cap
616.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States